Patent: 5,945,397
✉ Email this page to a colleague
Summary for Patent: 5,945,397
Title: | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
Abstract: | Human tumor necrosis factor receptor proteins having the of amino acids 1-235 are disclosed in SEQ ID NO:2. TNF receptor deletion variants having the sequence of amino acids 1-185 or 1-163 of SEQ ID NO:2 also display TNF bing activity. Murine TNF receptor proteins are also disclosed in SEQ ID NO:4 and are capable of binding TNF. |
Inventor(s): | Smith; Craig A. (Seattle, WA), Goodwin; Raymond G. (Seattle, WA), Beckmann; M. Patricia (Poulsbo, WA) |
Assignee: | Immunex Corporation (Seattle, WA) |
Application Number: | 08/650,000 |
Patent Claims: | see list of patent claims |
Details for Patent 5,945,397
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2009-09-11 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2009-09-11 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2009-09-11 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2009-09-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,945,397
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | 131871 | ⤷ Try a Trial |
Austria | 242322 | ⤷ Try a Trial |
Australia | 3970293 | ⤷ Try a Trial |
Australia | 4920993 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |